RHBDF2 and metabolic dysfunction-associated steatohepatitis: Further research has highlighted the role of IRHOM2 ubiquitination in regulating NASH progression, suggesting that targeting IRHOM2 could offer therapeutic potential in the management of NAFLD/NASH treatment [80, 81].